An expert review focused on multiple sclerosis suggests that extending anti-CD20 infusion intervals in stable patients may help preserve disease control while reducing long-term infection risk and immunoglobulin decline. The synthesis frames an individualized risk-management approach rather than defaulting to shorter intervals. In a separate real-world lens, an observational Italian study reported low atrial fibrillation incidence with zanubrutinib among chronic lymphocytic leukemia patients, with new-onset atrial fibrillation in 9 of 679 individuals. Together, the updates point to a broader safety playbook in hematology and immunology: tailoring intensity and monitoring for clinically meaningful adverse events instead of applying one schedule to all patients.